Advertisement
Canada markets closed

  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CAD/USD

    0.7283
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    79.30
    +0.31 (+0.39%)
     

  • Bitcoin CAD

    84,170.59
    -1,561.70 (-1.82%)
     

  • CMC Crypto 200

    1,304.14
    +9.46 (+0.73%)
     

  • GOLD FUTURES

    2,315.10
    -7.20 (-0.31%)
     

  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     

  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     

  • NASDAQ futures

    18,161.50
    -25.00 (-0.14%)
     

  • VOLATILITY

    13.00
    -0.23 (-1.74%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • NIKKEI 225

    38,131.00
    -71.37 (-0.19%)
     

  • CAD/EUR

    0.6775
    -0.0001 (-0.01%)
     

How Is Vertex Pharmaceuticals Positioned in October?

Kenneth Smith
Updated
How Is Vertex Pharmaceuticals Positioned in October?

Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.

Continue reading